MSFT 453.9631 -2.6353% AAPL 228.225 -2.0409% NVDA 131.2 -2.75% GOOGL 187.56 -1.8935% GOOG 189.16 -1.8167% AMZN 196.37 -1.7118% META 522.38 -2.3023% AVGO 1714.64 -1.7224% TSLA 265.3951 0.811% TSM 187.5 -1.8582% LLY 937.8 -0.2107% V 261.56 -0.5475% JPM 207.67 -0.0626% UNH 505.78 0.9682% NVO 141.2 -1.0789% WMT 69.41 -1.4203% LVMUY 154.5 1.9667% XOM 112.96 0.9292% LVMHF 770.5 1.6491% MA 432.89 -0.173%

Novo Nordisk A/S

Healthcare US NVO


Last update at 2024-07-11T14:55:00Z

Day Range


52 Week Range



  • Previous Close 142.74
  • Market Cap457910.98M
  • Volume914664
  • P/E Ratio41.58
  • Dividend Yield1.00%
  • EBITDA100106.00M
  • Revenue TTM214490.01M
  • Revenue Per Share TTM47.73
  • Gross Profit TTM 148506.00M
  • Diluted EPS TTM2.47


Income Statement


Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 69062.00M 59080.00M 53130.00M 48553.00M 47615.00M
Minority interest - - - 0.00000M 0.00000M
Net income 55525.00M 47757.00M 42138.00M 38951.00M 38628.00M
Selling general administrative 4467.00M 4050.00M 3958.00M 4007.00M 3916.00M
Selling and marketing expenses 46217.00M 37008.00M 32928.00M 31823.00M 29397.00M
Gross profit 148506.00M 117142.00M 106014.00M 101933.00M 94214.00M
Reconciled depreciation 7362.00M 6025.00M 5753.00M 5661.00M 3925.00M
Ebit 74809.00M 58644.00M 54126.00M 52483.00M 47239.00M
Ebitda 82040.00M 67556.00M 60215.00M 57791.00M 51164.00M
Depreciation and amortization 7231.00M 8912.00M 6089.00M 5308.00M 3925.00M
Non operating income net other - - - 0.00000M 0.00000M
Operating income 74809.00M 58644.00M 54126.00M 52483.00M 47248.00M
Other operating expenses 102145.00M 82156.00M 72820.00M 69538.00M 64583.00M
Interest expense 378.00M 2451.00M 390.00M 220.00M 85.00M
Tax provision 13537.00M 11323.00M 10992.00M 9602.00M 8987.00M
Interest income 239.00M 558.00M 337.00M 3757.00M 439.00M
Net interest income -320.00000M -180.00000M -203.00000M -436.00000M -106.00000M
Extraordinary items - - - 0.00000M 0.00000M
Non recurring - - - 0.00000M 0.00000M
Other items - - - 0.00000M 0.00000M
Income tax expense 13537.00M 11323.00M 10992.00M 9602.00M 8987.00M
Total revenue 176954.00M 140800.00M 126946.00M 122021.00M 111831.00M
Total operating expenses 73697.00M 58498.00M 51888.00M 49450.00M 46966.00M
Cost of revenue 28448.00M 23658.00M 20932.00M 20088.00M 17617.00M
Total other income expense net -5747.00000M 436.00M -996.00000M -3930.00000M 473.00M
Discontinued operations - - - 0.00000M 0.00000M
Net income from continuing ops 55525.00M 47757.00M 42138.00M 38951.00M 38628.00M
Net income applicable to common shares 55525.00M 47757.00M 42138.00M 38951.00M 38628.00M
Preferred stock and other adjustments - - - 0.00000M 0.00000M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 241257.00M 194508.00M 144922.00M 125612.00M 110769.00M
Intangible assets 46324.00M 38825.00M 20657.00M 5835.00M 5145.00M
Earning assets - - - - -
Other current assets 2727.00M 1690.00M 2332.00M 188.00M 204.00M
Total liab 157771.00M 123762.00M 81597.00M 68019.00M 58930.00M
Total stockholder equity 83486.00M 70746.00M 63325.00M 57593.00M 51839.00M
Deferred long term liab - - - 0.00000M 0.00000M
Other current liab 103887.00M 21784.00M 18370.00M 15819.00M 41850.00M
Common stock 456.00M 462.00M 470.00M 480.00M 490.00M
Capital stock 456.00M 462.00M 470.00M 480.00M 490.00M
Retained earnings 80587.00M 72004.00M 63774.00M 57817.00M 53406.00M
Other liab 12513.00M 11285.00M 8427.00M 6027.00M 4766.00M
Good will 5092.00M 4346.00M - 0.00000M 0.00000M
Other assets 13427.00M 8939.00M 6539.00M 4962.00M 2893.00M
Cash 12653.00M 10720.00M 12757.00M 15475.00M 15638.00M
Cash and equivalents - - - - -
Total current liabilities 120940.00M 99516.00M 70273.00M 58983.00M 54164.00M
Current deferred revenue - 55178.00M 38727.00M 35332.00M 5043.00M
Net debt 13131.00M 15925.00M -2401.00000M -10992.00000M -15123.00000M
Short term debt 1466.00M 13684.00M 7459.00M 1474.00M 515.00M
Short long term debt 480.00M 12862.00M 6684.00M 659.00M 515.00M
Short long term debt total 25784.00M 26645.00M 10356.00M 4483.00M 515.00M
Other stockholder equity -6.00000M -6.00000M -8.00000M -10.00000M -11.00000M
Property plant equipment 66671.00M 55362.00M 50269.00M 50551.00M 41891.00M
Total current assets 108194.00M 85595.00M 65809.00M 62456.00M 59067.00M
Long term investments 1343.00M 1441.00M 1648.00M 1808.00M 1773.00M
Net tangible assets 32070.00M 27575.00M 42668.00M 51758.00M 46694.00M
Short term investments 10921.00M 6765.00M - 0.00000M 0.00000M
Net receivables 57505.00M 46799.00M 32184.00M 29152.00M 26889.00M
Long term debt 20775.00M 9654.00M - 0.00000M 0.00000M
Inventory 24388.00M 19621.00M 18536.00M 17641.00M 16336.00M
Accounts payable 15587.00M 8870.00M 5717.00M 6358.00M 6756.00M
Total permanent equity - - - 0.00000M 0.00000M
Noncontrolling interest in consolidated entity - - - 0.00000M 0.00000M
Temporary equity redeemable noncontrolling interests - - - 0.00000M 0.00000M
Accumulated other comprehensive income 2449.00M -1714.00000M -911.00000M -694.00000M -2046.00000M
Additional paid in capital - - - 0.00000M 0.00000M
Common stock total equity - - 470.00M 480.00M 490.00M
Preferred stock total equity - - - 0.00000M 0.00000M
Retained earnings total equity - - - 0.00000M 0.00000M
Treasury stock - -6.00000M -8.00000M -10.00000M -11.00000M
Accumulated amortization - - - 0.00000M 0.00000M
Non currrent assets other 206.00M 267.00M 674.00M 841.00M 51702.00M
Deferred long term asset charges - - - 0.00000M 0.00000M
Non current assets total 133063.00M 108913.00M 79113.00M 63156.00M 51702.00M
Capital lease obligations 4529.00M 4129.00M 3672.00M 3824.00M 0.00000M
Long term debt total 24318.00M 12961.00M 2897.00M 3009.00M 0.00000M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -24918.00000M -5941.00000M -22436.00000M -11509.00000M -12080.00000M
Change to liabilities 6717.00M 3153.00M -641.00000M -398.00000M 1146.00M
Total cashflows from investing activities -24918.00000M -31605.00000M -22436.00000M -11509.00000M -12080.00000M
Net borrowings -2408.00000M 15471.00M 4732.00M -741.00000M 94.00M
Total cash from financing activities -51797.00000M -25493.00000M -32244.00000M -35484.00000M -34521.00000M
Change to operating activities 2631.00M 2185.00M 5.00M 441.00M -932.00000M
Net income 55525.00M 47757.00M 42138.00M 38951.00M 38628.00M
Change in cash 1934.00M -1507.00000M -3185.00000M -218.00000M -1529.00000M
Begin period cash flow 10719.00M 12226.00M 15411.00M 15629.00M 17158.00M
End period cash flow 12653.00M 10719.00M 12226.00M 15411.00M 15629.00M
Total cash from operating activities 78887.00M 55000.00M 51951.00M 46782.00M 44616.00M
Issuance of capital stock - - - - -
Depreciation 7362.00M 6025.00M 5753.00M 5661.00M 3925.00M
Other cashflows from investing activities -10165.00000M 4.00M 18.00M 20.00M 19.00M
Dividends paid 25303.00M 21517.00M 20121.00M 19409.00M 19048.00M
Change to inventory -4767.00000M -1085.00000M -895.00000M -1305.00000M -963.00000M
Change to account receivables -9917.00000M -12909.00000M -2822.00000M -2126.00000M -2621.00000M
Sale purchase of stock -24086.00000M -19447.00000M -16855.00000M -15334.00000M -15567.00000M
Other cashflows from financing activities 11215.00M 22160.00M 5682.00M -11509.00000M 94.00M
Change to netincome 22145.00M 10588.00M 8890.00M 6761.00M 5433.00M
Capital expenditures 14753.00M 7385.00M 22081.00M 11231.00M 12410.00M
Change receivables - - - 0.00000M 0.00000M
Cash flows other operating - - - 0.00000M 0.00000M
Exchange rate changes - - - 0.00000M 0.00000M
Cash and cash equivalents changes - - - 0.00000M 0.00000M
Change in working capital -5336.00000M -8656.00000M -4353.00000M -3388.00000M -3370.00000M
Stock based compensation 1539.00M 1040.00M 823.00M 363.00M 414.00M
Other non cash items 6260.00M -2489.00000M -3402.00000M -4407.00000M -3968.00000M
Free cash flow 64134.00M 47615.00M 29870.00M 35551.00M 32206.00M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
Novo Nordisk A/S
-1.54 1.08% 141.20 41.58 31.15 2.13 32.99 2.11 4.70
Novo Nordisk A/S
-0.09 0.06% 141.25 41.06 31.25 2.08 33.11 2.11 4.70
Vertex Pharmaceuticals Inc
-1.14 0.23% 490.48 29.67 24.33 10.38 5.83 9.33 20.00
Regeneron Pharmaceuticals Inc
10.39 0.97% 1081.52 29.07 20.12 7.57 3.82 6.95 19.42
3.19 3.15% 104.50 42.45 26.95 7.05 5.80 7.85 26.51

Reports Covered

Stock Research & News


Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company has a collaboration agreement with Gilead Sciences, Inc.; and research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Novo Nordisk A/S

Novo Allé 1, Bagsvaerd, Denmark, 2880

Key Executives

Name Title Year Born
Mr. Lars Fruergaard Jorgensen Pres, CEO & Member of Management Board 1966
Mr. Karsten Munk Knudsen Exec. VP, CFO & Member of the Management Board 1971
Mr. Henrik Ehlers Wulff Exec. VP, Head of Product Supply, Quality & IT and Member of the Management Board 1970
Ms. Camilla Sylvest Exec. VP, Head of Commercial Strategy & Corp. Affairs and Member of the Management Board 1972
Dr. Martin Holst Lange Exec. VP, Head of Devel. & Member of the Management Board 1970
Ms. Monique Carter Exec. VP, Head of People & Organisation and Member of Management Board 1973
Dr. Marcus Schindler Ph.D. EVP, Head of Research & Early Devel., Chief Scientific Officer & Member of the Management Board 1966
Mr. Maziar Mike Doustdar Exec. VP, Head of International Operations & Member of the Management Board 1970
Mr. Douglas J. Langa Exec. VP, Head of North America Operations & Member of Management Board 1966
Mr. Ludovic Helfgott Exec. VP, Head of Rare Disease & Member of Management Board 1974

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.